Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022
- ABX196 phase 1/2 study results for the treatment of hepatocellular carcinoma (HCC) were selected for a presentation at the ASCO Gastrointestinal Cancers Symposium 2022
- ABX196 at a maximum dose of 0.4µg was very well tolerated in combination with checkpoint inhibitor nivolumab
- 10 heavily pre-treated patients were included in the dose escalation phase of which 5 (50%) experienced a clinical benefit during the treatment period
- The results support the further clinical development of ABX196 in HCC
- ABX196 is Abivax's second compound in clinical development after lead drug-candidate ABX464